Q&A with Robert Hardy, Aesica - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Q&A with Robert Hardy, Aesica
Q&A with Robert Hardy, chief executive of Aesica

Pharmaceutical Technology
Volume 35, Issue 3, pp. 138

Q&A with
Robert Hardy, chief executive of Aesica

Robert Hardy
Do you see a new industry trend emerging?

One of the current trends is Big Pharma's commitment to remain with products after their patent expiries. To do so, they are looking at alternative, more cost-effective manufacturing sources. The benefits of flexibility, swift commercialization, minimal capital expenditure, and low scale-up costs are the key factors behind the significant market growth in contract manufacturing. Pharmaceutical companies are increasingly realizing the benefits of outsourcing manufacturing and packaging, which traditionally were managed in-house.

The most significant recent change is Big Pharma's realization that their massive infrastructures for development and manufacture are no longer sustainable in an environment where new chemical entities (NCEs) are harder and harder to bring to market. This realization has prompted mergers that starkly highlighted the new companies' manufacturing overcapacity. Most Big Pharma companies now are closely evaluating the long-term benefits of their site capabilities.

Moreover, pharmaceutical companies are looking to contract manufacturing companies to provide them with specialist technologies and facilities. Contractors can share the overhead of managing specific suites, either for sterile, controlled, or high-containment drugs. The increasing number of biopharmaceutical NCEs is rapidly boosting demand for specialist aseptic filling and lyophilization facilities. Biotechnology companies, the drivers of much of this innovation, are looking to contract development and manufacturing organizations to provide this first so they can avoid the risks of capital investment. They do not have to factor in time for capital investment into their development program, which could delay commercialization and extend time to market.

What is the most common demand your clients are currently making of you?

Clients expect the exact same service as delivered in previous years, but the challenging economic climate brings pressure to deliver services at increasingly competitive costs. The real key is to provide added value throughout the duration of the contract. It is possible to overcome such challenges by extending and enhancing one's capabilities.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here